Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 2/20 | 0.52 |
| ▸ | SREBF2 | Q12772 | 10/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | ATM | Q13315 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
| ▸ | PLAU | P00749 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL487201 | 0.85 | KDM4E (0.56) | KDM4ELMNACYP3A4TSHRRECQL | |
| SCHEMBL5102581 | 0.84 | KDM4E (0.47) | KDM4ELMNACYP3A4TSHRRECQL | |
| SCHEMBL10066451 | 0.83 | NOS3 (0.55) | KDM4ELMNACYP3A4TSHRRECQL | |
| SCHEMBL2935815 | 0.83 | RECQL (0.55) | KDM4ELMNACYP3A4TSHRRECQL | |
| SCHEMBL13541414 | 0.81 | RECQL (0.61) | TSHRRECQLMAOADYRK1AALDH1A1 | |
| SCHEMBL27756399 | 0.80 | KDM4E (0.51) | KDM4ELMNACYP3A4TSHRRECQL | |
| SCHEMBL3640229 | 0.80 | KDM4E (0.51) | KDM4ELMNACYP3A4TSHRRECQL | |
| SCHEMBL16544526 | 0.78 | CYP3A4 (0.50) | KDM4ELMNACYP3A4TSHRL3MBTL1 | |
| SCHEMBL18924478 | 0.78 | KDM4E (0.50) | KDM4ELMNACYP3A4TSHRRECQL | |
| SCHEMBL17520376 | 0.78 | KDM4E (0.58) | KDM4ELMNACYP3A4TSHRRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10927106-B2 | Benzothiazole derivatives as DYRK1 inhibitors | PHARMASUM THERAPEUTICS AS (NO) | 2021-02-23 | — | — | US | disclosed |
| US-9765065-B2 | Therapeutic substituted cyclopentanes | ALLERGAN, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-20170144999-A1 | THERAPEUTIC SUBSTITUTED CYCLOPENTANES | ALLERGAN, INC. | 2017-05-25 | — | — | US | disclosed |
| US-9591935-B2 | Therapeutic substituted cyclopentanes | ALLERGEN, INC. (US) | 2017-03-14 | — | — | US | disclosed |
| EP-2170345-B1 | THERAPEUTIC SUBSTITUTED CYCLOPENTANES FOR REDUCING INTRAOCULAR PRESSURE | ALLERGAN INC (US) | 2013-03-06 | — | — | EP | disclosed |
| US-20130030008-A1 | ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2013-01-31 | — | — | US | disclosed |
| US-8362073-B2 | Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals | SANOFI (FR) | 2013-01-29 | — | — | US | disclosed |
| US-20110152290-A1 | ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2011-06-23 | — | — | US | disclosed |
| US-20110062165-A1 | BALANCED INDIVIDUAL DINING PLATE | ALLERGAN INC | 2011-03-17 | — | — | US | disclosed |
| EP-2170345-A1 | THERAPEUTIC SUBSTITUTED CYCLOPENTANES FOR REDUCING INTRAOCULAR PRESSURE | Allergan, Inc. (US) | 2010-04-07 | — | — | EP | disclosed |
| WO-2009006370-A1 | THERAPEUTIC SUBSTITUTED CYCLOPENTANES FOR REDUCING INTRAOCULAR PRESSURE | ALLERGAN, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
| US-7342116-B2 | Process for producing heterocyclic aldehyde | KOEI CHEMICAL CO., LTD. (JP) | 2008-03-11 | — | — | US | disclosed |
| US-20050124807-A1 | oxidation of a hetero alcohol in presence od an 2,2,6,6-teraalkylpiperidin-1-oxy comound | KOEI CHEMICAL CO., LTD. (JP) | 2005-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10927106-B2 | Benzothiazole derivatives as DYRK1 inhibitors | DYRK1A, DYRK1B, PDK2 | KDM4E 984/4885LMNA 4785/4885CYP3A4 2557/4885 |
| US-20050124807-A1 | oxidation of a hetero alcohol in presence od an 2,2,6,6-teraalkylpiperidin-1-oxy comound | ADH1C, ADH1A, AOX1 | KDM4E 3250/4885LMNA 4168/4885CYP3A4 301/4885 |
| US-20110152290-A1 | ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | EDF1, LPAR2, LIPG | KDM4E 938/4885LMNA 1259/4885CYP3A4 4152/4885 |
| US-20170144999-A1 | THERAPEUTIC SUBSTITUTED CYCLOPENTANES | CYP11B2, CYP11B1, HMGCR | KDM4E 2506/4885LMNA 1312/4885CYP3A4 562/4885 |
| US-20130030008-A1 | ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | EDF1, LPAR2, LIPG | KDM4E 938/4885LMNA 1259/4885CYP3A4 4152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.